pcket No: AHP92038-2C

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

An immunogenic composition which produces an immune

response against HIV-1 infection in a human comprising an

Listing of Claims

Claim 17 (New)

Claims	1-16	(Canceled))
--------	------	------------	---

	intranasal or an intramuscular dosage of a recombinant
	adenovirus comprising an expression cassette containing a
	promoter, part or all of the HIV-1 gp160 sequence and a
	polyadenylation signal sequence.
Claim 18 (New)	The composition of claim 17, wherein the adenovirus is a
	serotype 4, a serotype 5 or a serotype 7 adenovirus.
Claim 19 (New)	The composition of claim 17, wherein the expression cassette
	further comprises part or all of the coding sequence for the
	HIV-1 rev gene inserted in frame after the HIV-1 gp160
	sequence and before the polyadenylation signal sequence.
Claim 20 (New)	The composition of claim 17, wherein the HIV-1 gp160
	sequence is the MN strain gp160 sequence or the LAV strain
	gp160 sequence.
Claim 21 (New)	The composition of claim 17, wherein the HIV-1 gp160
	sequence is replaced by a sequence encoding the gag-pro
	region of HIV-1.
Claim 22 (New)	The composition of claim 17, wherein the intranasal dosage is
	Claim 19 (New) Claim 20 (New) Claim 21 (New)

about 1 x 10⁷ pfu of virus.

Claim 23 (New)	The composition of claim 17, wherein the intramuscular dosage
	is in the range of about 1×10^7 to 2×10^9 pfu of virus.
Claim 24 (New)	The composition of claim 17, wherein the adenovirus
	comprises a deletion in the E3 gene.
Claim 25 (New)	The composition of claim 17, wherein the adenovirus
	comprises a deletion in the E3 gene and a deletion in the E1
	gene or the E4 gene.
Claim 26 (New)	A method for producing an immune response against HIV-1
	infection in a human comprising administering to the human an
	immunogenic composition comprising an intranasal or an
	intramuscular dosage of a recombinant adenovirus comprising
	an expression cassette containing a promoter, part or all of the
	HIV-1 gp160 sequence and a polyadenylation signal sequence.
Claim 27 (New)	The method of claim 26, further comprising the step of
	administering one or more intranasal or intramuscular booster
	dosages of the recombinant adenovirus.
	m
Claim 28 (New)	The method of claim 27, wherein the administering one or
Claim 28 (New)	The method of claim 27, wherein the administering one or more booster dosages of the recombinant adenovirus is
Claim 28 (New)	-
Claim 28 (New)	more booster dosages of the recombinant adenovirus is
Claim 28 (New)	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1
Claim 28 (New) Claim 29 (New)	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is
	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof.
	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof. The method of claims 26, wherein the adenovirus is a serotype
Claim 29 (New)	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof. The method of claims 26, wherein the adenovirus is a serotype 4, a serotype 5 or a serotype 7 adenovirus.
Claim 29 (New)	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof. The method of claims 26, wherein the adenovirus is a serotype 4, a serotype 5 or a serotype 7 adenovirus. The method of claim 26, wherein the expression cassette
Claim 29 (New)	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof. The method of claims 26, wherein the adenovirus is a serotype 4, a serotype 5 or a serotype 7 adenovirus. The method of claim 26, wherein the expression cassette further comprises part or all of the coding sequence for the
Claim 29 (New)	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof. The method of claims 26, wherein the adenovirus is a serotype 4, a serotype 5 or a serotype 7 adenovirus. The method of claim 26, wherein the expression cassette further comprises part or all of the coding sequence for the HIV-1 rev gene inserted in frame after the HIV-1 gp160
Claim 29 (New) Claim 30 (New)	more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof. The method of claims 26, wherein the adenovirus is a serotype 4, a serotype 5 or a serotype 7 adenovirus. The method of claim 26, wherein the expression cassette further comprises part or all of the coding sequence for the HIV-1 rev gene inserted in frame after the HIV-1 gp160 sequence and before the polyadenylation signal sequence.

ocket No: AHP92038-2C Patent

Claim 32 (New)	The method of claim 26, wherein the HIV-1 gp160 sequence is
	replaced by a sequence encoding the gag-pro region of HIV-1.
Claim 33 (New)	The method of claim 26, wherein the intranasal dosage is about
	1 x 10 ⁷ pfu of virus.
Claim 34 (New)	The method of claim 26, wherein the intramuscular dosage is in
	the range of about 1×10^7 to 2×10^9 pfu of virus.
Claim 35 (New)	The method of claim 27, wherein the intranasal booster dosage
	is in the range of about 1×10^7 to 1×10^8 pfu of virus.
Claim 36 (New)	The method of claim 27, wherein the intramuscular booster
	dosage is in the range of about 1×10^{10} to 8×10^8 pfu of virus.
Claim 37 (New)	The method of claim 28, wherein the antigen polypeptide
	dosage comprises between 200 µg and 0.5 mg of antigen
	polypeptide.
Claim 38 (New)	The method of claim 26, wherein the adenovirus comprises a
	deletion in the E3 gene.
Claim 39 (New)	The method of claim 26, wherein the adenovirus comprises a
	deletion in the E3 gene and a deletion in the E1 gene or the E5
	gene.